Results 131 to 140 of about 13,947 (241)

Bimekizumab 2‐year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Raj Chovatiya, Afsaneh Alavi, Takuya Miyagawa, Irina Turchin, Thrasyvoulos Tzellos, Hessel H. van der Zee, Christina Crater, Bartosz Lukowski, Nicola Tilt, Christos C. Zouboulis   +9 more
wiley   +1 more source

Vulvar Fibroadenoma: A Rare Differential Diagnosis of a Vulvar Mass

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Vulvar fibroadenoma is a rare benign tumor arising from mammary‐type tissue or mammary‐like anogenital glands. A 46‐year‐old Asian woman presented with a slowly enlarging painful labial mass and a history of gynecological disorders. Excision confirmed fibroadenoma, highlighting its inclusion in the differential diagnosis of vulvar masses.
Fatemeh Nili, Aysan Nozheh, Maryam Norouzi, Abolfazl Gilani   +3 more
wiley   +1 more source

Prevalence of Hidradenitis Suppurativa in Bucharest, Romania

INTRODUCTION: Hidradenitis suppurativa is a chronic inflammatory disease of the apocrine gland-bearing areas frequently misdiagnosed or underdiagnosed. Its true prevalence is still unknown and there is an ongoing interest in this matter.
Christensen, Robin, Jemec, Gregor B. E., Constantin, Maria-Magdalena, Bouazzi, Dorra, Serban, Elena-Daniela, Medianfar, Cecilia E.   +5 more
core   +1 more source

Hidradenitis suppurativa: MRI features in anogenital disease

, 2014
BACKGROUND: Hidradenitis suppurativa is a rare chronic inflammatory disorder of apocrine gland-bearing skin, which commonly affects the anogenital region.
Williams, Andrew, Irving, Peter, Desai, Nemesha, Sanderson, Jeremy, Griffin, Nyree, Anderson, Simon, Goh, Vicky; id_orcid   +6 more
core   +1 more source

Indicators of Suboptimal Treatment Among Patients With Crohn's Disease Treated With Ustekinumab or Risankizumab and Treatment Journey Among Ustekinumab Discontinuers in the United States

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background and Aims Patients with Crohn's disease (CD) may experience suboptimal response to advanced therapies (ATs), including interleukin (IL)‐12/23 inhibitor ustekinumab and IL‐23 inhibitor risankizumab. In an evolving treatment landscape, this study evaluated indicators of suboptimal treatment with these agents. Methods This retrospective
Freddy Caldera, Maryia Zhdanava, Sumesh Kachroo, Lilian Diaz, Aditi Shah, Fengyi Jiang, Caroline Kerner, Dominic Pilon, Jennifer Seminerio   +8 more
wiley   +1 more source

Experiences of Drainage and Associated Impacts: A Qualitative Study Among Patients With Hidradenitis Suppurativa

JEADV Clinical Practice, Volume 5, Issue 3, Page 846-853, September 2026.
This study provides an in‐depth account of patients' experiences of drainage as a symptom of hidradenitis suppurativa. The HIDE Scale© facilitates incorporation of these insights into clinical practice, supporting person‐centred approaches that enhance clinical assessment, reduce stigma, and strengthen patient–clinician communication.
Stine Thestrup Hansen, Bente Villumsen, Mina Shereen Khaled, Terri Shih, Steven Daveluy, Amit Garg, Susanne de Goeij, Barry M. McGrath, Peter Theut Riis, Kari Zalik, Jennifer L. Hsiao, Camilla G. Frederiksen, Noor F. Goandal, Hans Christian Ring, Joseph Dowsett, Rahul Masson, John R. Ingram, Gregor B. E. Jemec, Joslyn S. Kirby, Linnea Thorlacius, the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HiSTORIC)   +20 more
wiley   +1 more source

Isotretinoin and Hidradenitis Suppurativa a Conflictual Binomial: Investigation on Differential Response Rate Between Inflammatory and Follicular Phenotype

JEADV Clinical Practice, Volume 5, Issue 3, Page 912-916, September 2026.
A cohort of 21 HS patients treated with isotretinoin was enrolled in this study. The main outcome was HISCR50 achievement at week 16. Overall, 2/12 patients affected by follicular phenotype of HS and 2/9 patients affected by inflammatory phenotype of HS achieved HISCR50 at week 16. No significant difference was found in response to isotretinoin between
Maria Vittoria Cannizzaro, Flaminia Antonelli, Dalma Malvaso, Federica Pellegrini, Elena Ippoliti, Niccolò Gori, Ketty Peris   +6 more
wiley   +1 more source

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study

Fabrizio Martora,1 Claudio Marasca,2 Sara Cacciapuoti,1 Federica Fariello,1 Luca Potestio,1 Teresa Battista,1 Massimiliano Scalvenzi,1 Matteo Megna1 1Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II ...
Cacciapuoti S, Battista T, Marasca C, Fariello F, Megna M, Scalvenzi M, Potestio L, Martora F   +7 more
core  

Validated, Reliable, and Novel Skin Frailty Scale for Outpatient Usage and Its Association With Age, Sex, and Non‐Melanoma Skin Cancer: An Observational Study

JEADV Clinical Practice, Volume 5, Issue 3, Page 872-882, September 2026.
Skin frailty (SF) is a common condition affecting adults aged ≥65 years. However, the lack of a validated and reliable visual scale to assess SF severity is a barrier to clinical care and research. In this study, we developed a 9‐parameter Skin Frailty Score (SFS), validated by two board‐certified dermatologists and meeting item and scale level content
Po‐Han Ho, Farah Abou‐Taleb, Shufeng Li, Kiana Yekrang, Vijaytha Muralidharan, Pirunthan Pathmarajah, Sophia Katherine Longo, Zakia Rahman, Albert Sean Chiou, Anne Lynn S. Chang   +9 more
wiley   +1 more source

Pyoderma Gangrenosum: A Retrospective Cohort Study of Comorbidities and Therapies in Over 65,000 Patients in the TriNetX Database

JEADV Clinical Practice, Volume 5, Issue 3, Page 933-938, September 2026.
ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis associated with systemic inflammatory diseases and malignancy. Although biologic therapies demonstrate efficacy in PG, the extent of their real‐world use remains incompletely characterized.
Rhiannon Grange, Tara Sholji, Marra Aghajani, Cindy Kok, John Frew   +4 more
wiley   +1 more source